Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research

David Buchbinder, Diane J. Nugent, Ruta Brazauskas, Zhiwei Wang, Mahmoud D. Aljurf, Mitchell S. Cairo, Robert Chow, Christine Duncan, Lamis K. Eldjerou, Vikas Gupta, Gregory A. Hale, Joerg Halter, Brandon Hayes-Lattin, Jack W. Hsu, David A. Jacobsohn, Rammurti T. Kamble, Kimberly A. Kasow, Hillard M. Lazarus, Paulette Mehta, Kasiani C. MyersSusan K. Parsons, Jakob R. Passweg, Joseph Pidala, Vijay Reddy, Carmen M. Sales-Bonfim, Bipin N. Savani, Adriana Seber, Mohamed L. Sorror, Amir Steinberg, William A. Wood, Donna A. Wall, Jacek H. Winiarski, Lolie C. Yu, Navneet S. Majhail

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

With improvements in hematopoietic cell transplant (HCT) outcomes for severe aplastic anemia (SAA), there is a growing population of SAA survivors after HCT. However, there is a paucity of information regarding late effects that occur after HCT in SAA survivors. This study describes the malignant and nonmalignant late effects in survivors with SAA after HCT. A descriptive analysis was conducted of 1718 patients post-HCT for acquired SAA between 1995 and 2006 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The prevalence and cumulative incidence estimates of late effects are reported for 1-year HCT survivors with SAA. Of the HCT recipients, 1176 (68.5%) and 542 (31.5%) patients underwent a matched sibling donor (MSD) or unrelated donor (URD) HCT, respectively. The median age at the time of HCT was 20 years. The median interval from diagnosis to transplantation was 3 months for MSD HCT and 14 months for URD HCT. The median follow-up was 70 months and 67 months for MSD and URD HCT survivors, respectively. Overall survival at 1 year, 2 years, and 5 years for the entire cohort was 76% (95% confidence interval [CI]: 74-78), 73% (95% CI: 71-75), and 70% (95% CI: 68-72). Among 1-year survivors of MSD HCT, 6% had 1 late effect and 1% had multiple late effects. For 1-year survivors of URD HCT, 13% had 1 late effect and 2% had multiple late effects. Among survivors of MSD HCT, the cumulative incidence estimates of developing late effects were all

Original languageEnglish (US)
Pages (from-to)1776-1784
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Aplastic Anemia
Bone Marrow
Transplants
Research
Survivors
Unrelated Donors
Siblings
Tissue Donors
Transplant Recipients
Confidence Intervals
Incidence

Keywords

  • Allogeneic
  • Hematopoietic cell transplant
  • Late effects
  • Severe aplastic anemia
  • Survivorship

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia : A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research. / Buchbinder, David; Nugent, Diane J.; Brazauskas, Ruta; Wang, Zhiwei; Aljurf, Mahmoud D.; Cairo, Mitchell S.; Chow, Robert; Duncan, Christine; Eldjerou, Lamis K.; Gupta, Vikas; Hale, Gregory A.; Halter, Joerg; Hayes-Lattin, Brandon; Hsu, Jack W.; Jacobsohn, David A.; Kamble, Rammurti T.; Kasow, Kimberly A.; Lazarus, Hillard M.; Mehta, Paulette; Myers, Kasiani C.; Parsons, Susan K.; Passweg, Jakob R.; Pidala, Joseph; Reddy, Vijay; Sales-Bonfim, Carmen M.; Savani, Bipin N.; Seber, Adriana; Sorror, Mohamed L.; Steinberg, Amir; Wood, William A.; Wall, Donna A.; Winiarski, Jacek H.; Yu, Lolie C.; Majhail, Navneet S.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 12, 12.2012, p. 1776-1784.

Research output: Contribution to journalArticle

Buchbinder, D, Nugent, DJ, Brazauskas, R, Wang, Z, Aljurf, MD, Cairo, MS, Chow, R, Duncan, C, Eldjerou, LK, Gupta, V, Hale, GA, Halter, J, Hayes-Lattin, B, Hsu, JW, Jacobsohn, DA, Kamble, RT, Kasow, KA, Lazarus, HM, Mehta, P, Myers, KC, Parsons, SK, Passweg, JR, Pidala, J, Reddy, V, Sales-Bonfim, CM, Savani, BN, Seber, A, Sorror, ML, Steinberg, A, Wood, WA, Wall, DA, Winiarski, JH, Yu, LC & Majhail, NS 2012, 'Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research', Biology of Blood and Marrow Transplantation, vol. 18, no. 12, pp. 1776-1784. https://doi.org/10.1016/j.bbmt.2012.06.018
Buchbinder, David ; Nugent, Diane J. ; Brazauskas, Ruta ; Wang, Zhiwei ; Aljurf, Mahmoud D. ; Cairo, Mitchell S. ; Chow, Robert ; Duncan, Christine ; Eldjerou, Lamis K. ; Gupta, Vikas ; Hale, Gregory A. ; Halter, Joerg ; Hayes-Lattin, Brandon ; Hsu, Jack W. ; Jacobsohn, David A. ; Kamble, Rammurti T. ; Kasow, Kimberly A. ; Lazarus, Hillard M. ; Mehta, Paulette ; Myers, Kasiani C. ; Parsons, Susan K. ; Passweg, Jakob R. ; Pidala, Joseph ; Reddy, Vijay ; Sales-Bonfim, Carmen M. ; Savani, Bipin N. ; Seber, Adriana ; Sorror, Mohamed L. ; Steinberg, Amir ; Wood, William A. ; Wall, Donna A. ; Winiarski, Jacek H. ; Yu, Lolie C. ; Majhail, Navneet S. / Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia : A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 12. pp. 1776-1784.
@article{ee0b70def80c4e18bd1de96033c3291c,
title = "Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research",
abstract = "With improvements in hematopoietic cell transplant (HCT) outcomes for severe aplastic anemia (SAA), there is a growing population of SAA survivors after HCT. However, there is a paucity of information regarding late effects that occur after HCT in SAA survivors. This study describes the malignant and nonmalignant late effects in survivors with SAA after HCT. A descriptive analysis was conducted of 1718 patients post-HCT for acquired SAA between 1995 and 2006 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The prevalence and cumulative incidence estimates of late effects are reported for 1-year HCT survivors with SAA. Of the HCT recipients, 1176 (68.5{\%}) and 542 (31.5{\%}) patients underwent a matched sibling donor (MSD) or unrelated donor (URD) HCT, respectively. The median age at the time of HCT was 20 years. The median interval from diagnosis to transplantation was 3 months for MSD HCT and 14 months for URD HCT. The median follow-up was 70 months and 67 months for MSD and URD HCT survivors, respectively. Overall survival at 1 year, 2 years, and 5 years for the entire cohort was 76{\%} (95{\%} confidence interval [CI]: 74-78), 73{\%} (95{\%} CI: 71-75), and 70{\%} (95{\%} CI: 68-72). Among 1-year survivors of MSD HCT, 6{\%} had 1 late effect and 1{\%} had multiple late effects. For 1-year survivors of URD HCT, 13{\%} had 1 late effect and 2{\%} had multiple late effects. Among survivors of MSD HCT, the cumulative incidence estimates of developing late effects were all",
keywords = "Allogeneic, Hematopoietic cell transplant, Late effects, Severe aplastic anemia, Survivorship",
author = "David Buchbinder and Nugent, {Diane J.} and Ruta Brazauskas and Zhiwei Wang and Aljurf, {Mahmoud D.} and Cairo, {Mitchell S.} and Robert Chow and Christine Duncan and Eldjerou, {Lamis K.} and Vikas Gupta and Hale, {Gregory A.} and Joerg Halter and Brandon Hayes-Lattin and Hsu, {Jack W.} and Jacobsohn, {David A.} and Kamble, {Rammurti T.} and Kasow, {Kimberly A.} and Lazarus, {Hillard M.} and Paulette Mehta and Myers, {Kasiani C.} and Parsons, {Susan K.} and Passweg, {Jakob R.} and Joseph Pidala and Vijay Reddy and Sales-Bonfim, {Carmen M.} and Savani, {Bipin N.} and Adriana Seber and Sorror, {Mohamed L.} and Amir Steinberg and Wood, {William A.} and Wall, {Donna A.} and Winiarski, {Jacek H.} and Yu, {Lolie C.} and Majhail, {Navneet S.}",
year = "2012",
month = "12",
doi = "10.1016/j.bbmt.2012.06.018",
language = "English (US)",
volume = "18",
pages = "1776--1784",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia

T2 - A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research

AU - Buchbinder, David

AU - Nugent, Diane J.

AU - Brazauskas, Ruta

AU - Wang, Zhiwei

AU - Aljurf, Mahmoud D.

AU - Cairo, Mitchell S.

AU - Chow, Robert

AU - Duncan, Christine

AU - Eldjerou, Lamis K.

AU - Gupta, Vikas

AU - Hale, Gregory A.

AU - Halter, Joerg

AU - Hayes-Lattin, Brandon

AU - Hsu, Jack W.

AU - Jacobsohn, David A.

AU - Kamble, Rammurti T.

AU - Kasow, Kimberly A.

AU - Lazarus, Hillard M.

AU - Mehta, Paulette

AU - Myers, Kasiani C.

AU - Parsons, Susan K.

AU - Passweg, Jakob R.

AU - Pidala, Joseph

AU - Reddy, Vijay

AU - Sales-Bonfim, Carmen M.

AU - Savani, Bipin N.

AU - Seber, Adriana

AU - Sorror, Mohamed L.

AU - Steinberg, Amir

AU - Wood, William A.

AU - Wall, Donna A.

AU - Winiarski, Jacek H.

AU - Yu, Lolie C.

AU - Majhail, Navneet S.

PY - 2012/12

Y1 - 2012/12

N2 - With improvements in hematopoietic cell transplant (HCT) outcomes for severe aplastic anemia (SAA), there is a growing population of SAA survivors after HCT. However, there is a paucity of information regarding late effects that occur after HCT in SAA survivors. This study describes the malignant and nonmalignant late effects in survivors with SAA after HCT. A descriptive analysis was conducted of 1718 patients post-HCT for acquired SAA between 1995 and 2006 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The prevalence and cumulative incidence estimates of late effects are reported for 1-year HCT survivors with SAA. Of the HCT recipients, 1176 (68.5%) and 542 (31.5%) patients underwent a matched sibling donor (MSD) or unrelated donor (URD) HCT, respectively. The median age at the time of HCT was 20 years. The median interval from diagnosis to transplantation was 3 months for MSD HCT and 14 months for URD HCT. The median follow-up was 70 months and 67 months for MSD and URD HCT survivors, respectively. Overall survival at 1 year, 2 years, and 5 years for the entire cohort was 76% (95% confidence interval [CI]: 74-78), 73% (95% CI: 71-75), and 70% (95% CI: 68-72). Among 1-year survivors of MSD HCT, 6% had 1 late effect and 1% had multiple late effects. For 1-year survivors of URD HCT, 13% had 1 late effect and 2% had multiple late effects. Among survivors of MSD HCT, the cumulative incidence estimates of developing late effects were all

AB - With improvements in hematopoietic cell transplant (HCT) outcomes for severe aplastic anemia (SAA), there is a growing population of SAA survivors after HCT. However, there is a paucity of information regarding late effects that occur after HCT in SAA survivors. This study describes the malignant and nonmalignant late effects in survivors with SAA after HCT. A descriptive analysis was conducted of 1718 patients post-HCT for acquired SAA between 1995 and 2006 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The prevalence and cumulative incidence estimates of late effects are reported for 1-year HCT survivors with SAA. Of the HCT recipients, 1176 (68.5%) and 542 (31.5%) patients underwent a matched sibling donor (MSD) or unrelated donor (URD) HCT, respectively. The median age at the time of HCT was 20 years. The median interval from diagnosis to transplantation was 3 months for MSD HCT and 14 months for URD HCT. The median follow-up was 70 months and 67 months for MSD and URD HCT survivors, respectively. Overall survival at 1 year, 2 years, and 5 years for the entire cohort was 76% (95% confidence interval [CI]: 74-78), 73% (95% CI: 71-75), and 70% (95% CI: 68-72). Among 1-year survivors of MSD HCT, 6% had 1 late effect and 1% had multiple late effects. For 1-year survivors of URD HCT, 13% had 1 late effect and 2% had multiple late effects. Among survivors of MSD HCT, the cumulative incidence estimates of developing late effects were all

KW - Allogeneic

KW - Hematopoietic cell transplant

KW - Late effects

KW - Severe aplastic anemia

KW - Survivorship

UR - http://www.scopus.com/inward/record.url?scp=84869082862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869082862&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.06.018

DO - 10.1016/j.bbmt.2012.06.018

M3 - Article

C2 - 22863842

AN - SCOPUS:84869082862

VL - 18

SP - 1776

EP - 1784

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -